This content is machine translated Multiple myeloma DREAMM-7: Belamaf plus bortezomib and dexamethasone outperforms comparator therapy In patients with multiple myeloma, the disease is often refractory to first-line triple or quadruple therapies. The result: a relapse occurs. Therefore, effective second-line therapy combinations are needed that include...…
View Post 3 min This content is machine translated Multiple Myeloma Problems and opportunities in therapy highlighted in more detail One of the most important decisions that must be made at the beginning of a symptomatic myeloma is the appropriate therapy. While not yet curable, a number of good options…
View Post 3 min This content is machine translated Multiple Myeloma Individualized treatment management on the rise The formation of brain metastases is a dreaded development, especially in lung cancer. There is also an increasing focus on gender-specific differences in medicine. Multiple myeloma also has variables that…
View Post 4 min This content is machine translated Multiple Myeloma (MM) Prognostic factors, the role of leptin and MGUS in focus. Multiple myeloma results from the degeneration of a single plasma cell whose clones spread throughout the bone marrow. Overall, the disease occurs very rarely. However, it is one of the…
View Post 8 min This content is machine translated Hematology Leukemia, malignancy and co. on the test bench The annual meeting of the American Society of Hematology (ASH) is considered the most important congress on hematologic diseases worldwide. International experts again exchanged information on current research results and…
View Post 3 min This content is machine translated Hematologic neoplasms New findings change the standards of diagnostics and therapy There is a lot happening in the landscape of hematologic neoplasms. This year, several potentially standard-changing studies could be presented to Congress at . Fitting to the claim of the annual…
View Post 6 min This content is machine translated Multiple Myeloma CAR-T cells, autologous and allogeneic stem cell transplantation: Who is winning the race? Autologous stem cell transplantation is highly valued in the treatment of multiple myeloma. In recent decades, the use of allogeneic blood stem cell transplantation has also been tested, but despite…
View Post 5 min This content is machine translated Multiple Myeloma Focus on first-line therapy The innovation of recent years has long since found its way into first-line therapy in multiple myeloma. Thus, the EHA-ESMO Guidelines were amended accordingly in January. Daratumumab, a monoclonal antibody…
View Post 10 min This content is machine translated Multiple Myeloma A portrait of a multifaceted disease The introduction of new drugs has steadily improved the prognosis of patients with multiple myeloma over the past years. Diagnostics have also been expanded, in particular by cytogenetic analyses, which…
View Post 5 min This content is machine translated Relapsed/refractory multiple myeloma The BCMA molecule as a beacon of hope The prognosis in relapsed and refractory multiple myeloma (RRMM) remains grim. Now, at the annual meeting of the American Society of Hematology (ASH), data have been presented that raise faint…
View Post 2 min This content is machine translated Multiple Myeloma Challenge accepted: Breaking boundaries in therapy Multiple myeloma is rare, but is one of the most common tumors of bone and bone marrow. Annually, there are about six to eight new cases per 100,000 inhabitants. Almost…
